Targeting the Endocannabinoid System May Help Social Withdrawal in Schizophrenia

A drug that boosts endocannabinoid levels reversed social withdrawal in a rat model of schizophrenia, with the insular cortex identified as a key brain region.

Kumar, Aditya et al.·The European journal of neuroscience·2026·Preliminary Evidencepreclinical
RTHC-08404PreclinicalPreliminary Evidence2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
preclinical
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

The FAAH inhibitor URB597 reversed social withdrawal in PCP-treated rats (a schizophrenia model) but decreased social interaction in healthy controls. The agranular insular cortex emerged as a key neural substrate — pCREB levels in this region positively correlated with social interaction time (r=0.43).

Key Numbers

Six cortical regions analyzed. Agranular insular cortex pCREB correlated with social interaction (r=0.43, p<0.05). URB597 reversed social deficits in PCP-treated rats but reduced social behavior in healthy controls, showing state-dependent effects.

How They Did This

Rats were treated with PCP (schizophrenia model) or saline, then received FAAH inhibitor URB597 or vehicle. Social interaction was measured, and CREB/pCREB expression was analyzed in six prefrontal and insular cortical regions using immunohistochemistry.

Why This Research Matters

Social withdrawal is one of the most debilitating symptoms of schizophrenia and has no effective treatment. This study identifies both a therapeutic target (endocannabinoid system) and a brain region (insular cortex) that could guide drug development.

The Bigger Picture

The negative symptoms of schizophrenia — social withdrawal, flat affect, lack of motivation — remain the greatest unmet need in psychiatry. The endocannabinoid system's state-dependent effects (helping when impaired, not when normal) make it an unusually promising target.

What This Study Doesn't Tell Us

PCP model captures some but not all aspects of schizophrenia. Small sample sizes limit statistical power. Single-dose acute treatment — chronic effects unknown. Rat social behavior is a limited proxy for human social functioning.

Questions This Raises

  • ?Why does URB597 improve social behavior in the disease state but worsen it in healthy animals?
  • ?Could FAAH inhibitors be developed specifically for schizophrenia's negative symptoms?
  • ?What role does the insular cortex play in human social withdrawal?

Trust & Context

Key Stat:
Evidence Grade:
Single preclinical study with small sample sizes provides mechanistic insights but requires replication and clinical translation.
Study Age:
Published 2026, contributing to growing endocannabinoid-schizophrenia research.
Original Title:
Inhibition of Fatty Acid Amide Hydrolase Alters Cortical CREB Signaling and Social Behavior in a Rat Model of Schizophrenia.
Published In:
The European journal of neuroscience, 63(3), e70427 (2026)
Database ID:
RTHC-08404

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Could cannabis-related drugs help with schizophrenia symptoms?

A drug that boosts the body's own endocannabinoids (by blocking the enzyme FAAH) reversed social withdrawal in a rat model of schizophrenia — but importantly, this is not about cannabis itself, and cannabis use is generally not recommended for people with schizophrenia.

Why did the drug work differently in healthy vs. sick animals?

URB597 improved social behavior in schizophrenia-model rats but actually reduced it in healthy rats, suggesting the endocannabinoid system has different roles depending on brain state — which could allow targeted treatment of specific symptoms.

Read More on RethinkTHC

Cite This Study

RTHC-08404·https://rethinkthc.com/research/RTHC-08404

APA

Kumar, Aditya; Seillier, Lenka; Kuchař, Martin; Seillier, Alexandre. (2026). Inhibition of Fatty Acid Amide Hydrolase Alters Cortical CREB Signaling and Social Behavior in a Rat Model of Schizophrenia.. The European journal of neuroscience, 63(3), e70427. https://doi.org/10.1111/ejn.70427

MLA

Kumar, Aditya, et al. "Inhibition of Fatty Acid Amide Hydrolase Alters Cortical CREB Signaling and Social Behavior in a Rat Model of Schizophrenia.." The European journal of neuroscience, 2026. https://doi.org/10.1111/ejn.70427

RethinkTHC

RethinkTHC Research Database. "Inhibition of Fatty Acid Amide Hydrolase Alters Cortical CRE..." RTHC-08404. Retrieved from https://rethinkthc.com/research/kumar-2026-inhibition-of-fatty-acid

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.